Pharma

Your Article Summary

See Latest Articles

Morphine/naltrexone extended-release capsules (Embeda): Combination of mu-opioid agonist and mu-opioid antagonist approved for the management of moderate-to-severe pain when continuous analgesia is needed for an extended time period
Formulary , 11/02/09

This extended–release capsule contains a combination of morphine, a mu–opioid receptor agonist, and naltrexone, a mu–opioid receptor antagonist. This combination was approved on August 13, 2009, for the management of moderate–to–severe pain when a continuous, around–the–clock opioid analgesic is needed for an extended period of time.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals